Acquist is focused on the identification, development and commercialization of drugs that regulate the process of inflammation. Aquist is committed to developing innovative products to better the lives of people with chronic inflammatory disorders. The Company’s lead programs are in NASH and chronic gout.
The principals of our Company have extensive experience in discovering new drugs, optimizing lead compounds, pulling these leads to IND-ready FDA submissions and into clinical development from Phase 0 through Phase 4. Generally, we expect to take our candidates through completion of randomized trials and to seek partners to fully realize commercial opportunities.
We focus on identifying drug prototypes or compound families that have already been tested in patients but have not been targeted at inflammatory diseases. These conditions typically require extended treatment, and prior demonstration of safety in patients is a paramount consideration. We then narrow metabolic pathways to those that offer multiple “drugable” targets for our discovery chemistry program. Such “clinical proof-of-concept” reduces risk, identifies clinical markets of interest, and clarifies pathways for regulatory approval.